Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome

Richter’s syndrome (RS), also known as Richter’s transformation, is defined as a transformation of chronic lymphocytic leukemia (CLL) to a more aggressive subtype, typically diffuse large B-cell ly...

[1]  A. Schuh,et al.  An update for Richter syndrome – new directions and developments , 2017, British journal of haematology.

[2]  L. Medeiros,et al.  Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma , 2016, American journal of hematology.

[3]  H. Einsele,et al.  Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Rossi,et al.  Richter syndrome: pathogenesis and management. , 2016, Seminars in oncology.

[5]  M. Pfreundschuh,et al.  Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. , 2016, Blood.

[6]  T. Robak,et al.  Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy , 2015, Leukemia & lymphoma.

[7]  Albrecht Reichle,et al.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Döhner,et al.  Poor efficacy and tolerability of R‐CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation , 2014, American journal of hematology.

[9]  T. Habermann,et al.  Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients , 2013, British journal of haematology.

[10]  A. Nagler,et al.  Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marr , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Kipps,et al.  Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Kantarjian,et al.  Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome , 2001, Leukemia & lymphoma.

[13]  Hong Chang,et al.  Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia. , 2010, American journal of clinical pathology.